Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma

British Journal of Haematology

Volumn 132, Issue 4, 2006, Pages 503-511

  Georgakis, Georgios V ^a   Li, Yang ^a   Rassidakis, Georgios Z ^a   Medeiros, L Jeffrey ^a   Mills, Gordon B ^a   Younes, Anas ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Akt; Apoptosis; CD30; CD40; Hodgkin lymphoma; Receptor activator of nuclear factor kappa B

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ATENOLOL; CASPASE 9; CD30 ANTIGEN; CD40 LIGAND; CYCLIN D1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN MDM2; PROTEIN S6; QLT 394; SERINE; THREONINE; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CARRIER PROTEIN; CASP9 PROTEIN, HUMAN; CASPASE; CD30 LIGAND; CHROMONE DERIVATIVE; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; MORPHOLINE DERIVATIVE; PTEN PROTEIN, HUMAN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TNFSF8 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEQUENCE HOMOLOGY; UPREGULATION; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; FLOW CYTOMETRY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGENS, CD; APOPTOSIS; CARRIER PROTEINS; CASPASE 9; CASPASES; CD30 LIGAND; CD40 LIGAND; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CHROMONES; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G1 PHASE; HODGKIN DISEASE; HUMANS; MEMBRANE GLYCOPROTEINS; MORPHOLINES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TUMOR NECROSIS FACTORS;

EID: 33644859147     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05881.x     Document Type: Article

References (46)

1. Abbott R.T. Tripp S. Perkins S.L. Elenitoba-Johnson K.S. Lim M.S. 2003 Analysis of the PI-3-Kinase-PTEN-AKT pathway in human lymphoma and leukemia using a cell line microarray Modern Pathology 16 607 612
2. Andjelic S. Hsia C. Suzuki H. Kadowaki T. Koyasu S. Liou H.C. 2000 Phosphatidylinositol 3-kinase and NF-kappa B/Rel are at the divergence of CD40-mediated proliferation and survival pathways Journal of Immunology 165 3860 3867
3. Birle D. Bottini N. Williams S. Huynh H. deBelle I. Adamson E. Mustelin T. 2002 Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation Journal of Immunology 169 286 291
4. Carbone A. Gloghini A. Gattei V. Aldinucci D. Degan M. De Paoli P. Zagonel V. Pinto A. 1995 Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines Blood 85 780 789
5. Cuni S. Perez-Aciego P. Perez-Chacon G. Vargas J.A. Sanchez A. Martin-Saavedra F.M. Ballester S. Garcia-Marco J. Jorda J. Durantez A. 2004 A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells Leukemia 18 1391 1400
6. Deane J.A. Trifilo M.J. Yballe C.M. Choi S. Lane T.E. Fruman D.A. 2004 Enhanced T cell proliferation in mice lacking the p85beta subunit of phosphoinositide 3-kinase Journal of Immunology 172 6615 6625
7. Donahue A.C. Fruman D.A. 2003 Proliferation and survival of activated B cells requires sustained antigen receptor engagement and phosphoinositide 3-kinase activation Journal of Immunology 170 5851 5860
8. Donahue A.C. Fruman D.A. 2004 PI3K signaling controls cell fate at many points in B lymphocyte development and activation Seminars in Cell & Developmental Biology 15 183 197
9. Drexler H.G. 1993 Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines Leukemia & Lymphoma 9 1 25
10. Dutton A. Reynolds G.M. Dawson C.W. Young L.S. Murray P.G. 2005 Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR Journal of Pathology 205 498 506
11. Fiumara P. Snell V. Li Y. Mukhopadhyay A. Younes M. Gillenwater A.M. Cabanillas F. Aggarwal B.B. Younes A. 2001 Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines Blood 98 2784 2790
12. Fresno Vara J.A. Casado E. de Castro J. Cejas P. Belda-Iniesta C. Gonzalez-Baron M. 2004 PI3K/Akt signalling pathway and cancer Cancer treatment reviews 30 193 204
13. Fruman D.A. 2004 Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling Current Opinion in Immunology 16 314 320
14. Georgakis G.V. Li Y. Humphreys R. Andreeff M. O'Brien S. Younes M. Carbone A. Albert V. Younes A. 2005 Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death British Journal of Haematology 130 501 510
15. Glantschnig H. Fisher J.E. Wesolowski G. Rodan G.A. Reszka A.A. 2003 M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase Cell Death and Differentiation 10 1165 1177
16. Gruss H.J. Hirschstein D. Wright B. Ulrich D. Caligiuri M.A. Barcos M. Strockbine L. Armitage R.J. Dower S.K. 1994 Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease Blood 84 2305 2314
17. Gruss H.J. Ulrich D. Braddy S. Armitage R.J. Dower S.K. 1995 Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells European Journal of Immunology 25 2083 2089
18. Jaffe E.S. Harris N.L. Stein H. Vardiman J.W. 2001 World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues pp 244 253 IARC Press Lyon
19. Kim H.H. Shin H.S. Kwak H.J. Ahn K.Y. Kim J.H. Lee H.J. Lee M.S. Lee Z.H. Koh G.Y. 2003 RANKL regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway Faseb J 17 2163 2165
20. Lu Y. Wang H. Mills G.B. 2003 Targeting PI3K-AKT pathway for cancer therapy Reviews in Clinical and Experimental Hematology 7 205 228
21. Luo J. Manning B.D. Cantley L.C. 2003 Targeting the PI3K-Akt pathway in human cancer: rationale and promise Cancer Cell 4 257 262
22. Mandal M. Kim S. Younes M.N. Jasser S.A. El-Naggar A.K. Mills G.B. Myers J.N. 2005 The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells British Journal of Cancer 92 1899 1905
23. Miller S.J. Lou D.Y. Seldin D.C. Lane W.S. Neel B.G. 2002 Direct identification of PTEN phosphorylation sites FEBS Lett 528 145 153
24. Mills G.B. Lu Y. Fang X. Wang H. Eder A. Mao M. Swaby R. Cheng K.W. Stokoe D. Siminovitch K. Jaffe R. Gray J. 2001 The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy Seminars in Oncology 28 125 141
25. Mir S.S. Richter B.W. Duckett C.S. 2000 Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells Blood 96 4307 4312
26. Morrison J.A. Gulley M.L. Pathmanathan R. Raab-Traub N. 2004 Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma Cancer Research 64 5251 5260
27. Nagel S. Scherr M. Quentmeier H. Kaufmann M. Zaborski M. Drexler H.G. MacLeod R.A. 2005 HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3 Leukemia 19 841 846
28. Padmore L. An S. Gunby R.H. Kelly K. Radda G.K. Knox K.A. 1997 CD40-triggered protein tyrosine phosphorylation on Vav and on phosphatidylinositol 3-kinase correlates with survival of the Ramos-Burkitt lymphoma B cell line Cell Immunology 177 119 128
29. Paez J. Sellers W.R. 2003 PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling Cancer Treatment Reports 115 145 167
30. Parekh D.B. Katso R.M. Leslie N.R. Downes C.P. Procyk K.J. Waterfield M.D. Parker P.J. 2000 Beta1-integrin and PTEN control the phosphorylation of protein kinase C Biochemical journal 352 425 433
31. Poppema S. 1996 Immunology of Hodgkin's disease Bailliaere's Clinical Haematology 9 447 457
32. Rassidakis G.Z. Jones D. Thomaides A. Sen F. Lai R. Cabanillas F. McDonnell T.J. Medeiros L.J. 2002 Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections American Journal of Clinical Pathology 118 328 334
33. Sanchez-Margalet V. Goldfine I.D. Vlahos C.J. Sung C.K. 1994 Role of phosphatidylinositol-3-kinase in insulin receptor signaling: studies with inhibitor, LY294002 Biochemical and Biophysical Research Communications 204 446 452
34. Sansal I. Sellers W.R. 2004 The biology and clinical relevance of the PTEN tumor suppressor pathway Journal of Clinical Oncology 22 2954 2963
35. Stein H. Hummel M. 1999 Cellular origin and clonality of classic Hodgkin's lymphoma: immunophenotypic and molecular studies Seminars in Hematology 36 233 241
36. Sugatani T. Alvarez U.M. Hruska K.A. 2003 Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors Journal of Cellular Biochemistry 90 59 67
37. Tai Y.T. Podar K. Mitsiades N. Lin B. Mitsiades C. Gupta D. Akiyama M. Catley L. Hideshima T. Munshi N.C. Treon S.P. Anderson K.C. 2003 CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling Blood 101 2762 2769
38. Vazquez F. Ramaswamy S. Nakamura N. Sellers W.R. 2000 Phosphorylation of the PTEN tail regulates protein stability and function Molecular and Cellular Biology 20 5010 5018
39. Vazquez F. Grossman S.R. Takahashi Y. Rokas M.V. Nakamura N. Sellers W.R. 2001 Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex Journal of Biological Chemistry 276 48627 48630
40. Vivanco I. Sawyers C.L. 2002 The phosphatidylinositol 3-kinase AKT pathway in human cancer Nature Reviews Cancer 2 489 501
41. Younes A. Carbone A. 2003 Clinicopathologic and molecular features of Hodgkin's lymphoma Cancer Biology & Therapy 2 500 507
42. Younes A. Kadin M.E. 2003 Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy Journal of Clinical Oncology 21 3526 3534
43. Yusuf I. Zhu X. Kharas M.G. Chen J. Fruman D.A. 2004 Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors Blood 104 784 787
44. Zhao S. Konopleva M. Cabreira-Hansen M. Xie Z. Hu W. Milella M. Estrov Z. Mills G.B. Andreeff M. 2004 Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias Leukemia 18 267 275
45. Zheng B. Fiumara P. Li Y.V. Georgakis G. Snell V. Younes M. Vauthey J.N. Carbone A. Younes A. 2003 MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival Blood 102 1019 1027
46. Zheng B. Georgakis G.V. Li Y. Bharti A. McConkey D. Aggarwal B.B. Younes A. 2004 Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors Clinical Cancer Research 10 3207 3215